Otsuka and Lundbeck’s antidepressant Rexulti should be approved to treat Alzheimer’s disease-related agitation (AAD), according to FDA advisors – a move that could unlock a sizeable new ...
The question facing Lundbeck and Otsuka is whether they can persuade doctors to prescribe Rexulti over generic antipsychotics, anxiety medicines and antidepressants, which are already being used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results